Published in Clin Epigenetics on June 09, 2015
High-density array-CGH with targeted NGS unmask multiple noncontiguous minute deletions on chromosome 3p21 in mesothelioma. Proc Natl Acad Sci U S A (2016) 0.85
Institutional implementation of clinical tumor profiling on an unselected cancer population. JCI Insight (2016) 0.82
The Many Roles of BAF (mSWI/SNF) and PBAF Complexes in Cancer. Cold Spring Harb Perspect Med (2016) 0.81
Epigenetics of Aging and Alzheimer's Disease: Implications for Pharmacogenomics and Drug Response. Int J Mol Sci (2015) 0.79
SWI/SNF regulates a transcriptional program that induces senescence to prevent liver cancer. Genes Dev (2016) 0.75
Genome-wide methylation sequencing of paired primary and metastatic cell lines identifies common DNA methylation changes and a role for EBF3 as a candidate epigenetic driver of melanoma metastasis. Oncotarget (2016) 0.75
Ascorbate induces apoptosis in melanoma cells by suppressing Clusterin expression. Sci Rep (2017) 0.75
TET2 Negatively Regulates Nestin Expression in Human Melanoma. Am J Pathol (2016) 0.75
A New Chromatin-Cytoskeleton Link in Cancer. Mol Cancer Res (2016) 0.75
5-Hydroxymethylcytosine is an independent predictor of survival in malignant melanoma. Mod Pathol (2016) 0.75
Differential mutation frequencies in metastatic cutaneous squamous cell carcinomas versus primary tumors. Cancer (2016) 0.75
Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med (2010) 67.34
Mutations of the BRAF gene in human cancer. Nature (2002) 65.42
Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med (2011) 45.46
IDH1 and IDH2 mutations in gliomas. N Engl J Med (2009) 32.41
The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov (2012) 26.98
Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Sci Signal (2013) 19.54
Tet proteins can convert 5-methylcytosine to 5-formylcytosine and 5-carboxylcytosine. Science (2011) 14.29
Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. N Engl J Med (2012) 13.48
Tet-mediated formation of 5-carboxylcytosine and its excision by TDG in mammalian DNA. Science (2011) 13.16
A landscape of driver mutations in melanoma. Cell (2012) 12.61
The COSMIC (Catalogue of Somatic Mutations in Cancer) database and website. Br J Cancer (2004) 12.35
Improved survival with MEK inhibition in BRAF-mutated melanoma. N Engl J Med (2012) 11.72
Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med (2014) 10.38
High frequency of BRAF mutations in nevi. Nat Genet (2002) 9.95
Methylation of lysine 4 on histone H3: intricacy of writing and reading a single epigenetic mark. Mol Cell (2007) 9.73
Highly recurrent TERT promoter mutations in human melanoma. Science (2013) 8.40
Malignant melanoma: genetics and therapeutics in the genomic era. Genes Dev (2006) 4.24
Loss of 5-hydroxymethylcytosine is an epigenetic hallmark of melanoma. Cell (2012) 4.04
The genetic landscape of clinical resistance to RAF inhibition in metastatic melanoma. Cancer Discov (2013) 3.71
Isocitrate dehydrogenase 1 and 2 mutations in cancer: alterations at a crossroads of cellular metabolism. J Natl Cancer Inst (2010) 3.00
High EVI1 levels predict adverse outcome in acute myeloid leukemia: prevalence of EVI1 overexpression and chromosome 3q26 abnormalities underestimated. Blood (2008) 2.86
Global 5-hydroxymethylcytosine content is significantly reduced in tissue stem/progenitor cell compartments and in human cancers. Oncotarget (2011) 2.80
Evolutionary dynamics of cancer in response to targeted combination therapy. Elife (2013) 2.76
What a difference a hydroxyl makes: mutant IDH, (R)-2-hydroxyglutarate, and cancer. Genes Dev (2013) 2.31
DNA methylation: TET proteins-guardians of CpG islands? EMBO Rep (2011) 2.23
Rare missense variants in POT1 predispose to familial cutaneous malignant melanoma. Nat Genet (2014) 2.08
The landscape of somatic mutations in epigenetic regulators across 1,000 paediatric cancer genomes. Nat Commun (2014) 1.90
Genetic landscape of esophageal squamous cell carcinoma. Nat Genet (2014) 1.89
The risk of melanoma in airline pilots and cabin crew: a meta-analysis. JAMA Dermatol (2015) 1.86
UV and pigmentation: molecular mechanisms and social controversies. Pigment Cell Melanoma Res (2008) 1.78
Whole-genome sequencing reveals complex mechanisms of intrinsic resistance to BRAF inhibition. Ann Oncol (2014) 1.64
Genetic alterations and personalized medicine in melanoma: progress and future prospects. J Natl Cancer Inst (2014) 1.61
PRC2 loss amplifies Ras-driven transcription and confers sensitivity to BRD4-based therapies. Nature (2014) 1.60
The Society for Immunotherapy of Cancer consensus statement on tumour immunotherapy for the treatment of cutaneous melanoma. Nat Rev Clin Oncol (2013) 1.46
Exposure to indoor tanning without burning and melanoma risk by sunburn history. J Natl Cancer Inst (2014) 1.41
The melanoma revolution: from UV carcinogenesis to a new era in therapeutics. Science (2014) 1.37
MAP kinase signaling and inhibition in melanoma. Oncogene (2012) 1.35
Molecular biology. Demystifying DNA demethylation. Science (2011) 1.29
The epigenetic modifier EZH2 controls melanoma growth and metastasis through silencing of distinct tumour suppressors. Nat Commun (2015) 1.15
Global identification of MLL2-targeted loci reveals MLL2's role in diverse signaling pathways. Proc Natl Acad Sci U S A (2012) 1.14
Next-generation sequencing reveals frequent consistent genomic alterations in small cell undifferentiated lung cancer. J Clin Pathol (2014) 1.12
5-Methylcytosine and 5-hydroxymethylcytosine spatiotemporal profiles in the mouse zygote. PLoS One (2012) 1.09
Understanding the progression of melanocytic neoplasia using genomic analysis: from fields to cancer. Oncogene (2003) 1.05
A natural history of melanomas and dysplastic nevi: an atlas of lesions in melanoma-prone families. Cancer (2002) 1.05
Environmental exposures, epigenetic changes and the risk of lupus. Lupus (2014) 0.99
Targeted next generation sequencing identifies clinically actionable mutations in patients with melanoma. Pigment Cell Melanoma Res (2014) 0.98
Identification of a melanoma susceptibility locus and somatic mutation in TET2. Carcinogenesis (2014) 0.98
Driver mutations of cancer epigenomes. Protein Cell (2014) 0.98
Combination of RAF and MEK inhibition for the treatment of BRAF-mutated melanoma: feedback is not encouraged. Cancer Cell (2014) 0.96
5-Hydroxymethylcytosine as a useful marker to differentiate between malignant melanomas and benign melanocytic nevi. J Dermatol Sci (2013) 0.95
Exome sequencing identifies frequent mutation of MLL2 in non-small cell lung carcinoma from Chinese patients. Sci Rep (2014) 0.95
5-Hydroxymethylcytosine expression in metastatic melanoma versus nodal nevus in sentinel lymph node biopsies. Mod Pathol (2014) 0.93
Lighting a path to pigmentation: mechanisms of MITF induction by UV. Pigment Cell Melanoma Res (2010) 0.91
Clonal architectures and driver mutations in metastatic melanomas. PLoS One (2014) 0.89
Melanoma epigenetics: novel mechanisms, markers, and medicines. Lab Invest (2014) 0.89
Ecotropic viral integration site 1, stem cell self-renewal and leukemogenesis. Cancer Sci (2012) 0.87
EVI1 oncoprotein interacts with a large and complex network of proteins and integrates signals through protein phosphorylation. Proc Natl Acad Sci U S A (2013) 0.86
Mutator transposon activation after UV-B involves chromatin remodeling. Epigenetics (2010) 0.86
Understanding the biology of melanoma and therapeutic implications. Hematol Oncol Clin North Am (2014) 0.85
EVI1 inhibits apoptosis induced by antileukemic drugs via upregulation of CDKN1A/p21/WAF in human myeloid cells. PLoS One (2013) 0.83
Chromosome 10, frequently lost in human melanoma, encodes multiple tumor-suppressive functions. Cancer Res (2014) 0.80
Deciphering root causes of intrinsic BRAF inhibitor resistance in melanoma: ushering in a new genomics case reports feature for Annals of Oncology. Ann Oncol (2014) 0.79
Up close and personal: the challenges of precision medicine in melanoma. J Natl Cancer Inst (2014) 0.78